Based on a report yesterday from the Cook County Register, a settlement has apparently been reached between Abbvie and plaintiffs in the testosterone replacement therapy drug cases. Currently there are 25,000 cases pending and this settlement could bring to a close the latest chapter in life science mass product litigation. What has most likely prompted … Continue reading The Perils of Product Liability Insurance When Mass Litigation Strikes
The recent headline, “Opioid Lawsuits Look More Like A Tobacco Settlement Every Day” in Forbes grabbed my attention for reasons I will explain. As you know, I help life science companies develop and implement insurance programs that enables them to transfer risk to the insurance company. So when you see a headline that reads like … Continue reading Possible Opioid Settlement and the Role of Product Liability Insurance
Last week the issue of public companies having to do quarterly reports popped up in the news in a big way with the President tweeting and then speaking on the possibility of ending quarterly reporting. There are a lot of opinions out there on whether this is a good idea or bad idea. Some people … Continue reading How Changing the Reporting Period for Public Companies to Semiannual Could Impact the D&O Market
Skin in the game – that means your insurance broker actually having a vested interest in your success and the level of service you receive year in and year out. Skin in the game does not mean your broker having a greater financial interest in year one compared to subsequent years yet that is how … Continue reading Your Insurance Broker Has No Incentive to Retain You as a Client!!!!
Cornerstone Research always puts out great data and this report on Securities Class Action Filings for the first half of 2018 is no exception. I recommend you check out the full report which you can find here. These visuals really speak for themselves but the big takeaway is that if you are publicly traded company … Continue reading Why Securities Class Filings are a Reality for Publicly Traded Companies
Happy Friday! Here is what I am reading as we head into the weekend: Talk about hitting on a lot of points, super insightful article - Regeneron’s Billionaire Founder Battles The Drug Pricing System (Forbes). Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups (Xconomy) When healthcare devices go over the counter. An important … Continue reading Friday Morning’s Top Articles
Here is what I am reading this morning: Glaxo’s New Research Chief Loves Big Pharma. Now He Has To Fix It (Forbes) – Highly recommended read! 23andMe is raising up to $300M on top of what they have already raised, valuing them at $2.5B (PitchBook). Venture capital firms invested more than $738 million in Medtech … Continue reading Wednesday Morning Headlines